Voyager Therapeutics Inc To Discuss Strategic Collaboration With Neurocrine Biosciences Inc Call Transcript
Good morning, and welcome to Voyager Therapeutics conference call to discuss today's announcement of a strategic collaboration with Neurocrine Biosciences. (Operator Instructions) Please be advised that this call is being recorded at the company's request. A replay of today's call will be available on the Investors section of the company's website approximately 2 hours after completion of this call. I would now like to turn the call over to Pete Pfreundschuh, Chief Financial Officer. Please go ahead.
Thank you, and good morning. Earlier this morning, we issued a joint press release with Neurocrine, announcing a strategic collaboration between the 2 companies for the development and commercialization of Voyager's GBA1 program, 3 additional CNS rare disease gene therapy targets. This press release is available on our website.
On today's call, we will review highlights from the strategic collaboration and discuss the transformational value that this brings Voyager. We will also provide an update on
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |